April Pun is a consultant to Athyrium, where she previously was a Principal. April focuses on investments within the biotech, pharma, and consumer healthcare sectors. Representative investments include financings for Puma Biotechnology, Basilea, Revance Therapeutics, RVL Pharmaceuticals and BioCryst Pharmaceuticals.

Previously, April was in the Investment Banking Global Healthcare group at Bank of America Merrill Lynch. In that role, April focused on M&A, public and private capital raising, licensing deals, and a wide scope of advisory work for biotechnology and pharmaceutical companies.

April graduated with a B.S.E. in Biomedical Engineering with a minor in Finance from Duke University.